TNFR2/TNFRSF1B/CD120b/TNF-R2 Drug Discovery Landscape & Assay Solutions
- By admin
- 12 Aug 2026
- Comments
Market Intelligence, Clinical Progress, and High-Purity Reagents for Immuno-Oncology and Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TNFR2/TNFRSF1B/CD120b/TNF-R2 drug discovery.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TNFR2 ECD-Fc Fusion Protein. High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). Theoretical MW confirmed. | View TNFR2 Products |
| Gene Delivery | TNFR2 Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction. Preserve native conformation for flow cytometry and cell-based functional assays. | View TNFR2 Products |
| Benchmark Ab | Anti-TNFR2 (Clinical sequence biosimilar / Biosimilar Reference). Recombinant positive control for binding and functional assays. | View TNFR2 Products |
| Validator | TNFR2 siRNA Set. For knockdown verification and specificity controls in loss-of-function cellular assays. | View TNFR2 Products |
| Related Target A | TNFR1 (TNFRSF1A). Crucial for selectivity counter-screening to avoid systemic toxicity. 75% ECD homology requires strict counter-screening. | View TNFR1 Products |
| Related Target B | TNF-alpha (TNF). Primary ligand. Required for competitive binding, trimerization assays, and mechanism-of-action studies. | View TNF Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| TNFR1/TNFR2 Selectivity Screening (75% ECD homology) | Human TNFR1 & TNFR2 ECD-Fc proteins with strict mass spec identity confirmation; homolog panel for parallel counter-screening. |
| Cross-species Cyno/Mouse Preclinical Evaluation | Human/Mouse/Cynomolgus TNFR2 ortholog ECD proteins available with >95% purity; sequence divergence mapped for epitope prediction. |
| Receptor Clustering & Agonism Validation (Trimerization-dependent Signaling) | High-avidity ECD-Fc format preserves native cysteine-rich domain (CRD) structure for multivalent binding studies; full-length TNFR2 Lentivirus for stable reporter cell lines. |
| Lack of Positive Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives / Off-target Binding / Treg vs Effector Discrimination | Validated siRNA for specificity checks in loss-of-function cellular assays; TNFR2 Lentivirus enables FACS-based internalization and reporter assays for functional discrimination. |
Live TNFR2/TNFRSF1B/CD120b/TNF-R2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TNFR2 therapeutics is intensifying, with major players exploring two distinct biological pathways: antagonism for immuno-oncology (depleting regulatory T cells or blocking their suppressive function) and agonism for autoimmune diseases (expanding regulatory T cells). As first-generation therapies reach the clinic, the next wave of R&D is targeting highly specific Fc-engineered monoclonal antibodies, conditional formats, and bispecifics that can safely modulate the tumor microenvironment without triggering the severe systemic inflammatory responses historically associated with TNF pathway modulation. A critical differentiator is epitope-specific signaling modulation—distinguishing between CRD2-mediated antagonism and CRD3-mediated agonist potential.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antagonist mAb (Treg Depletion) | BioInvent, HiFiBiO Therapeutics, OncoNova, Bright Angel Therapeutics | Solid Tumors, Lymphoma, Immuno-Oncology | Fc-Receptor Binding Assays; TNFR1 Counter-screening (Need HEK293 expressed native antigens & high-purity TNFR1/TNFR2 proteins) |
| Agonist mAb / Mutein / Selective Agonist | Boston Immune Technologies, Tizona (Gilead), Academic Consortia | Autoimmune Diseases, Solid Tumors (IO) | Ligand Competition SPR; Oligomerization Assay (Need pure TNF-alpha & TNFR2 ECD; full-length Lentivirus cell lines) |
| Bispecific / Conditional Antibody | Various Biotechs, Emerging Biotech | Advanced Solid Tumors, Autoimmune | Heterodimer Validation; Internalization Assay (Need High-Purity Cross-reactive Abs & TNFR2-overexpressing cell lines) |
| Small Molecule | LUBAC Inhibitor Programs, Early Stage Academics | Refractory Inflammation, Inflammatory Disease | Selectivity Assay; Cell Line Construction (Need TNFR1 vs TNFR2 Homolog Panels; TNFR2 Lentivirus for stable lines) |
| Soluble Receptor / Fusion | Academic / Preclinical | Inflammatory Disease | Ligand Competition (Need TNFR2 ECD vs TNF binding pair) |